Reproducibility of Serologic Assays for Influenza Virus A (H5N1)
, Alan Heath, Diane Major, Robert W. Newman, Katja Hoschler, Wang Junzi, Jacqueline M. Katz, Jerry P. Weir, Maria C. Zambon, and John M. Wood
Author affiliations: University of Leicester, Leicester, UK (I. Stephenson); National Institute for Biological Standards and Controls, Potters Bar, UK (A. Heath, D. Major, R.W. Newman, J.M. Wood); Health Protection Agency, Colindale, UK (K. Hoschler, M.C. Zambon); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.M. Katz); Food and Drug Administration, Rockville, Maryland, USA (J.P. Weir); National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People’s Republic of China (W. Junzhi)
Figure 3. Range of hemagglutination-inhibition (HI) and neutralization titers to clade 2.2 and 2.3 heterologous NIBRG-23 and IBCDC-RG5 viruses in postvaccination serum sample F: the number of laboratories reporting specific titer dilution of absolute titers and titers relative to 07/150. A) Absolute horse HI titers, B) absolute neutralization titers, C) titers relative to 07/150 horse HI titers, D) titers relative to 07/150 neutralization titers.
Page created: November 01, 2010
Page updated: November 01, 2010
Page reviewed: November 01, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.